 
 
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: BB-10901 | IMGN901
                                 Compound class: 
                                                            Antibody
                                 
                                    
                                        Comment: Lorvotuzumab mertansine is an antibody-drug conjugate (ADC) combining an anti-NCAM1 (CD56) monoclonal antibody with the maytansinoid DM1 (PubChem CID 71301226) tubulin inhibitor [2]. Annotated peptide sequences for this antibody are available from its IMGT/mAb-db record. Patent US5639641 [4] describes the resurfacing of murine anti-CD56 monoclonal antibody N901, to improve its therapeutic efficacy in preparation for use as a human drug. A protein BLAST search matches the variable region of the light chain of lorvotuzumab, with sequence 36 from the patent, sequence 36 being a CDR grafted version of N901. No affinity data for the interaction between the preferred engineered antibody and the molecular target is provided in the patent. | 
| Classification  | |
| Compound class | Antibody | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 9299 | lorvotuzumab mertansine | 
| Synonyms  | 
| BB-10901 | IMGN901 | 
| Database Links  | |
| Specialist databases | |
| IMGT/mAb-DB | 58 | 
| Other databases | |
| GtoPdb PubChem SID | 178104003 | 
| PubChem SID | 178104003 | 
| Search PubMed clinical trials | lorvotuzumab mertansine | 
| Search PubMed titles | lorvotuzumab mertansine | 
| Search PubMed titles/abstracts | lorvotuzumab mertansine | 
| Wikipedia | Lorvotuzumab mertansine |